Key terms
About ACHL
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACHL news
Apr 04
5:19pm ET
Piper downgardes Achilles Therapeutics, says ‘step-function’ change needed
Apr 04
5:10pm ET
Achilles Therapeutics price target lowered to $6 from $11 at Chardan
Apr 04
4:14pm ET
Achilles Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Apr 04
6:53am ET
Achilles Therapeutics reports Q4 EPS (46c) vs. (61c) last year
Apr 04
6:35am ET
Achilles Therapeutics provides update on Phase I/IIa NSCLC results
No recent press releases are available for ACHL
ACHL Financials
Key terms
Ad Feedback
ACHL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACHL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
